New Anti-Covid Drug That Reduces Dependence on Oxygen Will Be Out in a Month: DRDO Scientist

| Updated: 10 May, 2021 6:59 am IST

The new anti-Covid oral drug developed by the DRDO

will help hospitalized patients and reduce their supplemental

oxygen dependence. The drug 2-deoxy-D-glucose (2-DG) has

been developed by the Institute of Nuclear Medicine and

Allied Sciences (INMAS), a leading laboratory of Defence Research and

Development Organization (DRDO), in collaboration with Dr Reddy’s

Laboratories (DRL) in Hyderabad. The drug, which comes in powder

form in a sachet and is taken orally by dissolving it in water, was approved

by the Drugs Controller General of India (DCGI) for emergency use as

an adjunct therapy. News18, in an exclusive with the DRDO Project

Director and Scientist of 2-DG, Dr Sudhir Chandana, explains how

anti-Covid-19 therapeutic application of the drug will work on patients.

Also Read Story

Assam CM accuses Rahul Gandhi of tourist visa status

NIA conducts raids against terror outfits in Kashmir

Defence Minister visits world’s highest battlefield

Supreme Court demands Baba Ramdev’s apology size equivalent to ads